Key result
Adjunctive intra-aortic balloon pump use in high risk reperfusion therapy significantly reduced long-term mortality (OR 0.63; 95% CI 0.45-0.90) compared to no IABP.
Why the study?
Does adjunctive intra-aortic balloon pump use reduce mortality in high-risk patients undergoing reperfusion therapy?
Meta-Analysis (n=2,037)
Yes
Does adjunctive intra-aortic balloon pump use reduce mortality in high-risk patients undergoing reperfusion therapy?
Effect estimate: OR 0.63 (95% CI 0.45-0.90)
Adjunctive IABP use in high-risk reperfusion therapy significantly improves long-term survival, especially in patients treated with contemporary PCI, despite no significant difference in 30-day mortality.
Supports adjunctive IABP in high-risk reperfusion; extends evidence to long-term survival despite neutral short-term results.
OBJECTIVE: Current literature shows there is widespread controversy regarding the indications and outcomes of using an intra-aortic balloon pump (IABP); furthermore, little is known about the late effects of IABP use. DESIGN: To determine whether IABP use can have beneficial effects for patients undergoing high risk reperfusion therapies, by conducting a meta-analysis of randomised trials. SETTING: Databases of Pubmed, Cochrane Library, and Clinicaltrials.gov were searched up to 15 June 2013. PATIENTS: Patients undergoing high risk reperfusion therapies. INTERVENTIONS: Randomised clinical trials comparing IABP with no IABP were considered eligible for this meta-analysis. MAIN OUTCOME MEASURES: Primary outcomes were early (30-day) and long term (≥ 6-month) mortality. RESULTS: Among the 1079 articles retrieved, 10 randomised studies with 2037 high risk patients were included in the quantitative analysis. Meta-analysis revealed that early mortality rate did not differ between the IABP group and the non-IABP group (OR 0.79, 95% CI 0.48 to 1.29). However, long term mortality was significantly reduced in the IABP group (OR 0.63, 95% CI 0.45 to 0.9), and this effect seemed more pronounced in the subset of patients treated with contemporary percutaneous coronary intervention (OR 0.55, 95% CI 0.38 to 0.80). Further analysis found that IABP use was associated with a reduced risk of 30-day re-ischaemia rate (OR 0.62, 95% CI 0.42 to 0.91) and the composite outcome of re-ischaemia and heart failure events (OR 0.75, 95% CI 0.58 to 0.98). No significant heterogeneity was observed. CONCLUSIONS: This meta-analysis suggests that adjunctive IABP use in high risk reperfusion therapy can improve long term survival.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2013) conducted a meta-analysis in High risk reperfusion therapy (n=2,037). Intra-aortic balloon pump (IABP) vs. No IABP was evaluated on Long term (≥ 6-month) mortality (OR 0.63, 95% CI 0.45-0.90). Adjunctive intra-aortic balloon pump use in high risk reperfusion therapy significantly reduced long-term mortality (OR 0.63; 95% CI 0.45-0.90) compared to no IABP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: